A Phase I Study of DN1406131 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs DN-1406131 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangxi Qingfeng Pharmaceutical
- 31 Jul 2019 Status changed from not yet recruiting to recruiting.
- 06 Sep 2018 According to Shanghai De Novo Pharmatech media release, the U.S. Food and Drug Adminiatrstion (FDA)'s approval of DN1406131's Investigational New Drug (IND) application in Jan 2018, Shanghai De Novo pharmatech Co., Ltd has received Clinical Trial Application (CTA) approval on May 29, 2018 from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with DN1406131.
- 28 Aug 2018 New trial record